Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | MRE11 | P49959 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585762 | 0.93 | FFAR1 (0.38) | FFAR1PTPN1PRMT5ADRB1ADRB3 | |
| SCHEMBL5585482 | 0.87 | FFAR1 (0.35) | FFAR1PRMT5ADRB1ADRB3HRH3 | |
| SCHEMBL5585329 | 0.84 | FFAR1 (0.38) | FFAR1PTPN1PRMT5ADRB1ADRB3 | |
| SCHEMBL5585432 | 0.83 | MRGPRX4 (0.51) | FFAR1PTPN1HRH3ALOX5KMT2A | |
| SCHEMBL5585411 | 0.78 | FFAR1 (0.44) | FFAR1PTPN1HRH3ALOX5KMT2A | |
| SCHEMBL5585855 | 0.76 | FFAR1 (0.41) | FFAR1PTPN1HRH3ALOX5KMT2A | |
| SCHEMBL5585812 | 0.76 | MEN1 (0.40) | FFAR1HRH3ALOX5KMT2AMEN1 | |
| SCHEMBL5585457 | 0.69 | FFAR1 (0.44) | FFAR1PTPN1HRH3ALOX5MRE11 | |
| SCHEMBL5585658 | 0.69 | KMT2A (0.46) | FFAR1PTPN1HRH3ALOX5KMT2A | |
| SCHEMBL5585524 | 0.69 | FFAR1 (0.44) | FFAR1PTPN1HRH3ALOX5MRE11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | FFAR1 868/4885PTPN1 2/4885PRMT5 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.